Glioblastoma Multiforme (GBM)-Pipeline Review, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline Review, H1 2017


  • Products Id :- GMDHC9467IDB
  • |
  • Pages: 1430
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Glioblastoma Multiforme (GBM)-Pipeline Review, H1 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM)-Pipeline Review, H1 2017, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial cells known as astrocytes. Signs and symptoms include slowly progressive neurologic deficit, usually motor weakness, headache, generalized symptoms of increased intracranial pressure, including headaches, nausea and vomiting, and cognitive impairment and seizures. Treatment includes radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 102, 55, 1, 5, 158, 22 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 10, 15, 1, 32 and 9 molecules, respectively.

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).

The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 10

Glioblastoma Multiforme (GBM)-Overview 11

Glioblastoma Multiforme (GBM)-Therapeutics Development 12

Glioblastoma Multiforme (GBM)-Therapeutics Assessment 57

Glioblastoma Multiforme (GBM)-Companies Involved in Therapeutics Development 83

Glioblastoma Multiforme (GBM)-Drug Profiles 181

Glioblastoma Multiforme (GBM)-Dormant Projects 1365

Glioblastoma Multiforme (GBM)-Discontinued Products 1375

Glioblastoma Multiforme (GBM)-Product Development Milestones 1377

Appendix 1388

List of Figures

Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Products under Development by Companies, H1 2017 (Contd..16), H1 2017

Products under Development by Companies, H1 2017 (Contd..17), H1 2017

Products under Development by Companies, H1 2017 (Contd..18), H1 2017

Products under Development by Companies, H1 2017 (Contd..19), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Number of Products by Stage and Molecule Type, H1 2017 (Contd..1), H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by AbbVie Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Actuate Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Advantagene Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Advenchen Laboratories LLC, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Affimed GmbH, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Agenus Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Ambrx Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Amgen Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Ampio Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by AngioChem Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Apac Biotech Pvt Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by apceth Biopharma GmbH, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by APIM Therapeutics AS, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Apogenix GmbH, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Ariad Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Arog Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Astellas Pharma Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by AstraZeneca Plc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Athenex Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Autotelic Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Basilea Pharmaceutica Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Batu Biologics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Bayer AG, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Beactica AB, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by BeiGene (Beijing) Co Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Berg LLC, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Bexion Pharmaceuticals LLC, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Bio-Path Holdings Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Bioasis Technologies Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by BioCancell Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Biomar Microbial Technologies, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Bioncotech Therapeutics SL, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Biovista Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Boston Biomedical Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Bristol-Myers Squibb Company, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Cantex Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Cavion LLC, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Celgene Corp, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Celldex Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Cellmid Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Celsion Corp, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by ChemoCentryx Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by CLL Pharma SA, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Coherus BioSciences Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Cortice Biosciences Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Critical Outcome Technologies Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Cynata Therapeutics Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by CytoVac A/S, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by CytRx Corp, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Deciphera Pharmaceuticals LLC, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by DEKK-TEC Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by DelMar Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Diffusion Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Ecrins Therapeutics SAS, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Eisai Co Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Eli Lilly and Company, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by EnGeneIC Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by EntreChem SL, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by ERC Belgium SA, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Evotec AG, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by FirstString Research Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Gene Techno Science Co Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Genentech Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Genisphere LLC, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Genor BioPharma Co Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by GlaxoSmithKline Plc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by GlioPharma ApS, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by GtreeBNT Co Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by GW Pharmaceuticals Plc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Hamlet Pharma AB, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Hutchison China MediTech Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Immatics Biotechnologies GmbH, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Immune Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by ImmunoCellular Therapeutics Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Immunomedics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Immunomet Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Immunomic Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Immupharma Plc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Incyte Corp, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Infinity Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Innovation Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Inspyr Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Insys Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Ipsen SA, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Johnson & Johnson, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Juno Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Kadmon Corp LLC, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by KaloBios Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Karyopharm Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Kite Pharma Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Komipharm International Co Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Les Laboratoires ServierSAS, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Lion Biotechnologies Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Lixte Biotechnology Holdings Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Loxo Oncology Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Mabion SA, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by MacroGenics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Mateon Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Medicenna Therapeutics Corp, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by MedImmune LLC, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Merck & Co Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Merck KGaA, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Midatech Pharma Plc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by MimiVax LLC, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Moleculin Biotech Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Mycenax Biotech Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by NanoCarrier Co Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Nanomerics Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Nektar Therapeutics, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Neonc Technologies Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Neumedicines Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by NewLink Genetics Corp, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Northwest Biotherapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Novartis AG, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Novogen Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Noxxon Pharma AG, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Nuo Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by NuvOx Pharma LLC, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Omniox Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Oncobiologics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Oncodesign SA, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Onconova Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Oncternal Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Orphit SAS, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Oryx GmbH & Co KG, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Ovensa Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Peloton Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Peptomyc SL, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Peregrine Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Pfizer Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by PharmAbcine Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by PharmaCyte Biotech Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Pharmicell Co Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Phoenix Biotechnology Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by PIQUR Therapeutics AG, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Plex Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Plexxikon Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Prana Biotechnology Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Progenics Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by PTC Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Puma Biotechnology Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Regulus Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by ReNeuron Group Plc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Rexahn Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Rgenix Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Richter Gedeon Nyrt, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Sanofi, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Sapience Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Scancell Holdings Plc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Sigma-Tau SpA, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by SignPath Pharma Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by SOM Biotech SL, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Sorrento Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by StemGen SpA, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Stemline Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Sunesis Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Susavion Biosciences Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Symphogen A/S, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Systimmune Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Terpenoid Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Therapeia GmbH & Co KG, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Threshold Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Tocagen Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by TRACON Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Transgene SA, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Trillium Therapeutics Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by TVAX Biomedical Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Tyme Technologies Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Upsher-Smith Laboratories Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Vascular Biogenics Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Vault Pharma Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Vaximm AG, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by VBI Vaccines Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by VCN Biosciences SL, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Vertex Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by ViraTherapeutics GmbH, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by X4 Pharmaceuticals Inc, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by Yooyoung Pharm Co Ltd, H1 2017

Glioblastoma Multiforme (GBM)-Pipeline by ZIOPHARM Oncology Inc, H1 2017

Glioblastoma Multiforme (GBM)-Dormant Projects, H1 2017

Glioblastoma Multiforme (GBM)-Dormant Projects, H1 2017 (Contd..1), H1 2017

Glioblastoma Multiforme (GBM)-Dormant Projects, H1 2017 (Contd..2), H1 2017

Glioblastoma Multiforme (GBM)-Dormant Projects, H1 2017 (Contd..3), H1 2017

Glioblastoma Multiforme (GBM)-Dormant Projects, H1 2017 (Contd..4), H1 2017

Glioblastoma Multiforme (GBM)-Dormant Projects, H1 2017 (Contd..5), H1 2017

Glioblastoma Multiforme (GBM)-Dormant Projects, H1 2017 (Contd..6), H1 2017

Glioblastoma Multiforme (GBM)-Dormant Projects, H1 2017 (Contd..7), H1 2017

Glioblastoma Multiforme (GBM)-Dormant Projects, H1 2017 (Contd..8), H1 2017

Glioblastoma Multiforme (GBM)-Dormant Projects, H1 2017 (Contd..9), H1 2017

Glioblastoma Multiforme (GBM)-Discontinued Products, H1 2017

Glioblastoma Multiforme (GBM)-Discontinued Products, H1 2017 (Contd..1), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AbbVie Inc

Actuate Therapeutics Inc

Advantagene Inc

Advenchen Laboratories LLC

Affimed GmbH

Agenus Inc

Ambrx Inc

Amgen Inc

Ampio Pharmaceuticals Inc

AngioChem Inc

Apac Biotech Pvt Ltd

apceth Biopharma GmbH

APIM Therapeutics AS

Apogenix GmbH

Ariad Pharmaceuticals Inc

Arog Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Athenex Inc

Autotelic Inc

Basilea Pharmaceutica Ltd

Batu Biologics Inc

Bayer AG

Beactica AB

BeiGene (Beijing) Co Ltd

Berg LLC

Bexion Pharmaceuticals LLC

BeyondSpring Pharmaceuticals Inc

Bio-Path Holdings Inc

Bioasis Technologies Inc

BioCancell Ltd

Biomar Microbial Technologies

Bioncotech Therapeutics SL

Biovista Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Cantex Pharmaceuticals Inc

Cavion LLC

Celgene Corp

Celldex Therapeutics Inc

Cellmid Ltd

Celsion Corp

ChemoCentryx Inc

CLL Pharma SA

Coherus BioSciences Inc

Cortice Biosciences Inc

Critical Outcome Technologies Inc

Cynata Therapeutics Ltd

CytoVac A/S

CytRx Corp

Daiichi Sankyo Company Ltd

Deciphera Pharmaceuticals LLC

DEKK-TEC Inc

DelMar Pharmaceuticals Inc

Diffusion Pharmaceuticals Inc

Dr. Reddy Laboratories Ltd

Ecrins Therapeutics SAS

Eisai Co Ltd

Eli Lilly and Company

EnGeneIC Ltd

EntreChem SL

ERC Belgium SA

Evotec AG

F. Hoffmann-La Roche Ltd

FirstString Research Inc

Gene Techno Science Co Ltd

Genentech Inc

Genisphere LLC

Genor BioPharma Co Ltd

GlaxoSmithKline Plc

GlioPharma ApS

GtreeBNT Co Ltd

GW Pharmaceuticals Plc

Hamlet Pharma AB

Hanmi Pharmaceuticals Co Ltd

Hutchison China MediTech Ltd

Immatics Biotechnologies GmbH

Immune Pharmaceuticals Inc

ImmunoCellular Therapeutics Ltd

Immunomedics Inc

Immunomet Therapeutics Inc

Immunomic Therapeutics Inc

Immupharma Plc

Incyte Corp

Infinity Pharmaceuticals Inc

Innovation Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

Insys Therapeutics Inc

Ipsen SA

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Kadmon Corp LLC

KaloBios Pharmaceuticals Inc

Karyopharm Therapeutics Inc

Kite Pharma Inc

Komipharm International Co Ltd

Kyorin Pharmaceutical Co Ltd

Les Laboratoires ServierSAS

Lion Biotechnologies Inc

Lixte Biotechnology Holdings Inc

Loxo Oncology Inc

Mabion SA

MacroGenics Inc

Mateon Therapeutics Inc

Medicenna Therapeutics Corp

MedImmune LLC

Merck & Co Inc

Merck KGaA

Midatech Pharma Plc

Millennium Pharmaceuticals Inc

MimiVax LLC

Moleculin Biotech Inc

Mycenax Biotech Inc

NanoCarrier Co Ltd

Nanomerics Ltd

Nektar Therapeutics

Neonc Technologies Inc

Neumedicines Inc

NewLink Genetics Corp

Northwest Biotherapeutics Inc

Novartis AG

Novogen Ltd

Noxxon Pharma AG

Nuo Therapeutics Inc

NuvOx Pharma LLC

Omniox Inc

Oncobiologics Inc

Oncodesign SA

Onconova Therapeutics Inc

Oncternal Therapeutics Inc

Ono Pharmaceutical Co Ltd

Orphit SAS

Oryx GmbH & Co KG

Ovensa Inc

Peloton Therapeutics Inc

Peptomyc SL

Peregrine Pharmaceuticals Inc

Pfizer Inc

PharmAbcine Inc

PharmaCyte Biotech Inc

Pharmicell Co Ltd

Phoenix Biotechnology Inc

PIQUR Therapeutics AG

Plex Pharmaceuticals Inc

Plexxikon Inc

Prana Biotechnology Ltd

Progenics Pharmaceuticals Inc

PTC Therapeutics Inc

Puma Biotechnology Inc

Regulus Therapeutics Inc

ReNeuron Group Plc

Rexahn Pharmaceuticals Inc

Rgenix Inc

Richter Gedeon Nyrt

Sanofi

Sapience Therapeutics Inc

Scancell Holdings Plc

Sigma-Tau SpA

SignPath Pharma Inc

SOM Biotech SL

Sorrento Therapeutics Inc

StemGen SpA

Stemline Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sunesis Pharmaceuticals Inc

Susavion Biosciences Inc

Symphogen A/S

Systimmune Inc

Terpenoid Therapeutics Inc

Therapeia GmbH & Co KG

Threshold Pharmaceuticals Inc

Tocagen Inc

TRACON Pharmaceuticals Inc

Transgene SA

Trillium Therapeutics Inc

TVAX Biomedical Inc

Tyme Technologies Inc

Upsher-Smith Laboratories Inc

Vascular Biogenics Ltd

Vault Pharma Inc

Vaximm AG

VBI Vaccines Inc

VCN Biosciences SL

Vertex Pharmaceuticals Inc

ViraTherapeutics GmbH

X4 Pharmaceuticals Inc

Yooyoung Pharm Co Ltd

ZIOPHARM Oncology Inc

Glioblastoma Multiforme (GBM) Therapeutic Products under Development, Key Players in Glioblastoma Multiforme (GBM) Therapeutics, Glioblastoma Multiforme (GBM) Pipeline Overview, Glioblastoma Multiforme (GBM) Pipeline, Glioblastoma Multiforme (GBM) Pipeline Assessment

select a license
Single User License
USD 2500 INR 175000
Site License
USD 5000 INR 350000
Corporate User License
USD 7500 INR 525000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com